Mexia 10, 10mg 50 tablets — Made in Turkey — Free Delivery

Mexia tablets are used for Alzheimer's disease from mild to severe forms.

Active ingredient: memantine;

1 coated tablet contains memantine hydrochloride 10 mg or 20 mg;

10 mg tablets: microcrystalline cellulose, DC lactose (contains lactose, povidone), colloidal silicon dioxide, talc, magnesium stearate, Opadry Y-January 7000 White coating (contains hypromellose, titanium dioxide (E 171), polyethylene glycol);

20 mg tablets: microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, Opadry Pink 20 coating A34056 (contains hypromellose, hydroxypropyl cellulose, talc, titanium dioxide (E 171), iron oxide red (E172), iron oxide black (E172)).

Hypersensitivity to the active substance or to any component of the preparation.

Treatment should be started and carried out under medical supervision. Therapy should be started only if there is a guardian who will regularly monitor the patient's intake of the preparation.

Tablets should be taken 1 time per day every day at the same time. Tablets can be taken with or without food.

The preparation  should not be used during pregnancy, except in cases due to a clear and obvious need.

The preparation should not be used in children due to insufficient data on safety and efficacy.

Moderate to severe Alzheimer's disease usually results in impaired ability to drive and use machines. Also, memantine has a slight to moderate effect on the rate of human reaction, therefore outpatients should be warned to take extra care when driving vehicles or operating equipment.

Experience is limited.

Relatively significant overdoses (200 mg and 105 mg over 3 days, respectively) were either associated with symptoms of fatigue, weakness and/or diarrhea, or were asymptomatic. In overdose up to 140 mg or an unspecified dose, symptoms of central nervous system disorders (confusion, lethargy, drowsiness, dizziness, agitation, aggression, hallucinations, gait disturbances) and / or gastrointestinal disorders (vomiting and diarrhea) were observed. After taking 2000 mg of memantine, the patient developed a coma for 10 days, later diplopia and agitation. After symptomatic treatment and plasmapheresis, the patient recovered without sequelae.

Treatment is symptomatic, there is no specific antidote. Standard clinical procedures should be used to remove the active substance from the body, for example, gastric lavage, activated charcoal, methods of acidifying the urine reaction, forced diuresis. In case of excessive general stimulation of the central nervous system, symptomatic therapeutic measures should be used with caution.

From the immune system: often - hypersensitivity.

On the part of the psyche: often - drowsiness; infrequently - confusion, hallucinations; indefinite - psychotic reactions.

From the nervous system: often - dizziness, imbalance; infrequently - gait disturbance; very rarely - convulsive seizures.

From the side of the heart: infrequently - heart failure.

From the side of the vessels: often - arterial hypertension; infrequently - venous thrombosis / thromboembolism.

From the respiratory system: often - shortness of breath.

From the gastrointestinal tract: often - constipation; infrequently - vomiting; indefinite - pancreatitis.

From the side of the liver and biliary tract: often - an increase in liver function; indefinite - hepatitis.

The simultaneous use of memantine and amantadine should be avoided due to the risk of developing pharmacotoxic psychosis. Both compounds are chemically linked NMDA antagonists. The same may apply to ketamine and dextromethorphan.

There is evidence regarding the risk of psychosis with the combined use of memantine and phenytoin.

Store below 25°C in original packaging.

Keep out of the reach of children.

Shelf life - 3 years.